Business
Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved in Japan to Treat ATTR-CM
In the Japanese Phase 3 study, 0% mortality was reported over the 30-month treatment period and acoramidis was well-tolerated The approval was based on a Japanese Phase 3 study and the global ATTRibute-CM Phase 3 trial, which demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date. Key data from the ATTRibute-CM study include: In as few as 3 months, the time to first event (all-cause mortality (ACM) or cardiovascular-related hospitalization (CVH)) durably separated relat
About this update from Bridgebio Pharma, Inc.
[{"type":"image","alt":"BridgeBio Pharma, Inc.","displaySize":"","headline":null,"caption":"BridgeBio Pharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":134,"url":"https://media.zenfs.com/en/globenewswire.com/95609e0a840873fa0736db3ba42e9949"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Iq7DUj1HEdREiIfZ9M6K3g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/95609e0a840873fa0736db3ba42e9949","width":300,"height":134}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"In the Japanese Phase 3 study, 0% mortality was reported over the 30-month treatment period and acoramidis was well-tolerated","length":125,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":125,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"The approval was based on a Japanese Phase 3 study and the global ATTRibute-CM Phase 3 trial, which demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date. Key data from the ATTRibute-CM study include:","length":227,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"In as few as 3 months, the time to first event (all-cause mortality (ACM) or cardiovascular-related hospitalization (CVH)) durably separated relative to placebo","length":160,"tagName":"p"}]},{"val":[{"type":"text","content":"A 42% reduction in composite ACM and recurrent CVH events relative to placebo at Month 30","length":89,"tagName":"p"}]},{"val":[{"type":"text","content":"A 50% reduction in the cumulative frequency of CVH events relative to placebo at Month 30","length":89,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":338,"olType":false}]}],"tagName":"ul","bulletedList":true,"length":565,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"BridgeBio will receive a $30 million milestone payment from Alexion, AstraZeneca Rare Disease, with royalties in the low double digits on net sales of Beyonttra in Japan","length":169,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":169,"olType":false},{"type":"text","content":"PALO ALTO, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced the Japanese Min...